Literature DB >> 12699847

Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan.

Kyoji Moriya1, Yoshizumi Shintani, Hajime Fujie, Hideyuki Miyoshi, Takeya Tsutsumi, Hiroshi Yotsuyanagi, Shiro Iino, Satoshi Kimura, Kazuhiko Koike.   

Abstract

Hepatitis C virus (HCV) infection is associated with the development of steatosis in the liver. Recently, infection with genotype 3a HCV has been reported to have a closer association with hepatic steatosis than that with genotype 1 or 2 HCV. Moreover, infection with genotype 3a HCV but not with genotype 1 has been shown to be associated with serum hypocholesterolemia or hypobetalipoproteinemia in European countries. We conducted a case control study to characterize the serum lipid profile in patients infected with genotype 1b HCV, which is the most prevalent HCV genotype in Japan. These patients had significantly lower serum cholesterol levels than those infected with HBV or genotype 2a HCV who had similar liver disease progression and body mass index. Further analysis of serum apolipoproteins revealed that not only apolipoprotein B but also apolipoprotein CII and apolipoprotein CIII levels were significantly reduced, while apolipoprotein AI, AII and E levels were similar in patients infected with genotype 1b HCV and those with HBV or genotype 2a HCV. These results indicate that, in Japan, infection with genotype 1b HCV is a cause of lipid metabolism disturbances, which may be associated with the pathogenesis of hepatitis C liver disease.

Entities:  

Year:  2003        PMID: 12699847     DOI: 10.1016/s1386-6346(02)00309-1

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  20 in total

1.  Vitamins B status and antioxidative defense in patients with chronic hepatitis B or hepatitis C virus infection.

Authors:  Chun-Che Lin; Wen-Hu Liu; Zhi-Hong Wang; Mei-Chin Yin
Journal:  Eur J Nutr       Date:  2010-12-24       Impact factor: 5.614

2.  Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C.

Authors:  Shunsuke Sato; Takuya Genda; Katsuharu Hirano; Hironori Tsuzura; Yoshio Kanemitsu; Yutaka Narita; Tetsu Kikuchi; Katsuyori Ijima; Takafumi Ichida
Journal:  Hepatol Int       Date:  2011-04-02       Impact factor: 6.047

Review 3.  Lipid testing in infectious diseases: possible role in diagnosis and prognosis.

Authors:  Sebastian Filippas-Ntekouan; Evangelos Liberopoulos; Moses Elisaf
Journal:  Infection       Date:  2017-05-08       Impact factor: 3.553

Review 4.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

5.  Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

Authors:  Josephine H Li; Xiang Qian Lao; Hans L Tillmann; Jennifer Rowell; Keyur Patel; Alexander Thompson; Sunil Suchindran; Andrew J Muir; John R Guyton; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection.

Authors:  Ornit Chiba-Falek; Colton Linnertz; John Guyton; Stephen D Gardner; Allen D Roses; Jeanette J McCarthy; Keyur Patel
Journal:  Hum Genet       Date:  2012-08-17       Impact factor: 4.132

Review 7.  Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy.

Authors:  Bente Magny Bergersen
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2.

Authors:  Nobuyoshi Seki; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Haruya Ishiguro; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Masato Matsushima; Yoshio Aizawa
Journal:  Hepatol Int       Date:  2014-09-26       Impact factor: 6.047

Review 9.  Lipids and HCV.

Authors:  M F Bassendine; D A Sheridan; S H Bridge; D J Felmlee; R D G Neely
Journal:  Semin Immunopathol       Date:  2012-10-31       Impact factor: 9.623

10.  Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients.

Authors:  Klaus Langohr; Arantza Sanvisens; Daniel Fuster; Jordi Tor; Isabel Serra; Celestino Rey-Joly; Inmaculada Rivas; Roberto Muga
Journal:  Open AIDS J       Date:  2008-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.